Jazz Pharmaceuticals plc

NasdaqGS:JAZZ 株式レポート

時価総額：US$6.8b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Jazz Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Jazz Pharmaceuticals'の CEO はBruce Cozaddで、 Jan2003年に任命され、 の在任期間は 21.42年です。 の年間総報酬は$ 15.34Mで、 7.8%給与と92.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.5%を直接所有しており、その価値は$ 36.20M 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と11.5年です。

主要情報

Bruce Cozadd

最高経営責任者

US$15.3m

報酬総額

CEO給与比率7.8%
CEO在任期間21.7yrs
CEOの所有権0.5%
経営陣の平均在職期間5yrs
取締役会の平均在任期間11.3yrs

経営陣の近況

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Recent updates

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18
Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jun 23
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jun 21

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Aug 24

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Aug 18

CEO報酬分析

Jazz Pharmaceuticals の収益と比較して、Bruce Cozadd の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

US$395m

Mar 31 2024n/an/a

US$331m

Dec 31 2023US$15mUS$1m

US$415m

Sep 30 2023n/an/a

US$80m

Jun 30 2023n/an/a

-US$87m

Mar 31 2023n/an/a

-US$156m

Dec 31 2022US$17mUS$1m

-US$224m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$450m

Dec 31 2021US$16mUS$1m

-US$330m

Sep 30 2021n/an/a

-US$161m

Jun 30 2021n/an/a

US$40m

Mar 31 2021n/an/a

US$518m

Dec 31 2020US$13mUS$1m

US$239m

Sep 30 2020n/an/a

US$179m

Jun 30 2020n/an/a

US$133m

Mar 31 2020n/an/a

US$280m

Dec 31 2019US$15mUS$1m

US$523m

Sep 30 2019n/an/a

US$609m

Jun 30 2019n/an/a

US$656m

Mar 31 2019n/an/a

US$486m

Dec 31 2018US$11mUS$979k

US$447m

Sep 30 2018n/an/a

US$520m

Jun 30 2018n/an/a

US$434m

Mar 31 2018n/an/a

US$447m

Dec 31 2017US$10mUS$950k

US$488m

報酬と市場: Bruceの 総報酬 ($USD 15.34M ) は、 US市場 ($USD 8.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Bruceの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Bruce Cozadd (60 yo)

21.7yrs

在職期間

US$15,341,235

報酬

Mr. Bruce C. Cozadd serves as an Independent Director of Acelyrin, Inc. since March 7, 2022 and also serves as its Chairman of Board since January 2023. He served as Member of Board of Advisors at Cellares...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Bruce Cozadd
Co-Founder21.7yrsUS$15.34m0.51%
$ 34.8m
Renee Gala
President & COOless than a yearUS$5.43m0.027%
$ 1.8m
Patricia Carr
Senior VP & Chief Accounting Officer5.1yrsUS$1.40mデータなし
Neena Patil
Executive VP & Chief Legal Officer5.2yrsUS$3.88m0.018%
$ 1.2m
Robert Iannone
Executive VP5.3yrsUS$4.98m0.046%
$ 3.1m
Philip Johnson
Executive VP & CFOless than a yearデータなし0.019%
$ 1.3m
Andrea Flynn
VP & Head of Investor Relationsno dataデータなしデータなし
Heidi Manna
Executive VP & Chief People Officer5.8yrsデータなしデータなし
Jed Black
Senior Vice President of Sleep & CNS Medicineno dataデータなしデータなし
Samantha Pearce
Executive VP & Chief Commercial OfficerChief Commercial Officer4.5yrsデータなし0.010%
$ 705.6k
John Miller
Senior Vice President of Corporate Strategy5yrsデータなしデータなし
Mary Henderson
Senior Vice President of Technical Operations1.1yrsデータなし0.0021%
$ 140.9k

5.0yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: JAZZの経営陣は経験豊富で経験豊富です（平均在職期間は5年）。

取締役

名称ポジション在職期間報酬所有権
Bruce Cozadd
Co-Founder21.7yrsUS$15.34m0.51%
$ 34.8m
Kenneth O'Keefe
Independent Director20.7yrsUS$513.77k0.045%
$ 3.1m
Seamus Mulligan
Independent Director12.7yrsUS$531.27k1.89%
$ 128.8m
Norbert Riedel
Independent Director11.3yrsUS$533.77k0.020%
$ 1.3m
Patrick Gerald Enright
Independent Director15.2yrsUS$526.27k0.034%
$ 2.3m
Patrick Kennedy
Independent Directorless than a yearデータなしデータなし
Rick Winningham
Lead Independent Director14.3yrsUS$571.27k0.015%
$ 987.4k
Jennifer Cook
Independent Non-Executive Director3.8yrsUS$533.77k0.0088%
$ 595.4k
Laura Hamill
Independent Directorless than a yearデータなし0.0024%
$ 165.4k
Heather McSharry
Independent Director11.3yrsUS$543.77k0.025%
$ 1.7m
Mark Smith
Independent Non-Executive Director3.8yrsUS$521.27k0.0088%
$ 595.4k
Anne O'Riordan
Independent Director5.6yrsUS$523.77k0.018%
$ 1.2m

11.3yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: JAZZの 取締役会 は経験豊富で 経験豊富 です ( 11.5年の平均在任期間)。